Time to redefine Myeloma.
Pratt G et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13620. [Epub ahead of print].

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Majithia N et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24131. [Epub ahead of print].

Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma.
Gonsalves WI et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24129. [Epub ahead of print].

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13608. [Epub ahead of print].

Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Rawstron AC et al. Cytometry B Clin Cytom. 2015 Jul 22. doi: 10.1002/cyto.b.21272. [Epub ahead of print].

Systematic review of the relationship between artificial sweetener consumption and cancer in humans: analysis of 599,741 participants.
Mishra A et al. Int J Clin Pract. 2015 Jul 23. doi: 10.1111/ijcp.12703. [Epub ahead of print].

Clinical Features and Survival of 338 Multiple Myeloma Patients Treated with Hematopoietic Stem Cell Transplantation or Conventional Chemotherapy.
Pérez R et al. Eur J Haematol. 2015 Jul 17. doi: 10.1111/ejh.12611. [Epub ahead of print].

Multiple Myeloma-Better Drugs Ask for More Stringent Evaluations.
Sonneveld P. JAMA Oncol. 2015 Jul 2. doi: 10.1001/jamaoncol.2015.2009. [Epub ahead of print].

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ et al. Eur J Haematol. 2015 Jul 14. doi: 10.1111/ejh.12633. [Epub ahead of print].

The Characterization of Adrenal Insufficiency and Identification of its Risk Factors in Patients with Plasma Cell Dyscrasias.
Tremblay D et al. Am J Hematol. 2015 Jul 15. doi: 10.1002/ajh.24118. [Epub ahead of print].

The Detection of Pancreatic and Retroperitoneal Plasmacytoma Helped to Diagnose Multiple Myeloma: A Case Report.
Utsumi T et al. Medicine (Baltimore). 2015 Jul;94(27):e914. doi: 10.1097/MD.0000000000000914.

An update on the use of lenalidomide for the treatment of multiple myeloma.
Zagouri F et al. Expert Opin Pharmacother. 2015 Aug;16(12):1865-77. doi: 10.1517/14656566.2015.1067681. Epub 2015 Jul 13.

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M et al. Haematologica. 2015 Jul 9. pii: haematol.2015.127548. [Epub ahead of print].

Hematopoietic cell and renal transplantation in plasma cell dyscrasia patients.
Baraldi O et al. Cell Transplant. 2015 Jul 8. [Epub ahead of print].

Fish consumption and risk of myeloma: a meta-analysis of epidemiological studies.
Wang YZ et al. Cancer Causes Control. 2015 Jul 9. [Epub ahead of print].

Preferred and actual place of death in haematological malignancy.
Howell DA et al. BMJ Support Palliat Care. 2015 Jul 8. pii: bmjspcare-2014-000793. doi: 10.1136/bmjspcare-2014-000793. [Epub ahead of print].

Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents.
Matsue K et al. Leuk Lymphoma. 2015 Jul 7:1-6. [Epub ahead of print].

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O et al. Cytometry B Clin Cytom. 2015 Jul 3. doi: 10.1002/cyto.b.21273. [Epub ahead of print].

Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale.
Bonanad S et al. J Geriatr Oncol. 2015 Jun 29. pii: S1879-4068(15)00053-3. doi: 10.1016/j.jgo.2015.03.003. [Epub ahead of print].

Gradual Increase of Chronic Lymphocytic Leukemia Incidence in Korea, 1999-2010: Comparison to Plasma cell myeloma.
Lee SJ et al. Leuk Lymphoma. 2015 Jul 1:1-19. [Epub ahead of print].

Leisure-time spent sitting and site-specific cancer incidence in a large US cohort.
Patel AV et al. Cancer Epidemiol Biomarkers Prev. 2015 Jun 30. pii: cebp.0237.2015. [Epub ahead of print].

Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.
Pulte D et al. Br J Haematol. 2015 Jun 30. doi: 10.1111/bjh.13537. [Epub ahead of print].

Multiple myeloma.
Persaud H. JAAPA. 2015 Jul;28(7):47-8. doi: 10.1097/01.JAA.0000466597.15540.54.

Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.
Jamani K et al. Leuk Lymphoma. 2015 Jul 7:1-6. [Epub ahead of print].

A Qualitative Investigation of Health Care Professionals’, Patients’ and Partners’ Views on Psychosocial Issues and Related Interventions for Couples Coping with Cancer.
Regan T et al. PLoS One. 2015 Jul 29;10(7):e0133837. doi: 10.1371/journal.pone.0133837. eCollection 2015.

Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Dimopoulos MA et al. Ann Oncol. 2015 Jul 27. pii: mdv325. [Epub ahead of print].